Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02276547 · ClinicalTrials.gov registry record · NA

Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System

A NA study of Mitral Valve Regurgitation, sponsored by Shockwave Medical.

Active
Registry status
NA
Development phase
27
Enrollment target
10
Study locations

NCT02276547 is a NA study of Mitral Valve Regurgitation that is active but no longer recruiting, run by Shockwave Medical. The registered enrollment target is 27 participants, below the 812-participant average among 11 other Mitral Valve Regurgitation trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02276547, a NA study of Mitral Valve Regurgitation, is active but no longer recruiting, sponsored by Shockwave Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
27 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to evaluate the safety and initial performance of the Neovasc Tiara Mitral Transcatheter Heart Valve with the Tiara Transapical Delivery System.

Conditions Studied

Interventions

  • DEVICE Mitral valve replacement

Study Locations (10)

California

  • Cedars Sinai Medical Center - Los Angeles

Illinois

  • Northwestern University - Chicago

Michigan

  • Henry Ford Health System - Detroit

Missouri

  • Washington University - St Louis

New York

  • Columbia University Medical Center - New York

Washington

  • University of Washington Medical Center - Seattle

Other

  • ZNA Middelheim - Antwerp

Alberta

  • University of Alberta - Edmonton

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2014-12
Est. Completion 2025-08
Phase NA

Sponsor

Shockwave Medical

13 total trials

What the Registry Record Tells You About NCT02276547

The ClinicalTrials.gov registry entry for NCT02276547 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 812-participant average among 11 other Mitral Valve Regurgitation trials with a reported enrollment target (97% lower). The listed sponsor is Shockwave Medical, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mitral Valve Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which Mitral valve replacement is the first listed.

NCT02276547 reports 10 study locations spanning 10 distinct geographic areas - top geographies include California, Illinois, Michigan.

Frequently Asked Questions

What is clinical trial NCT02276547 about?

NCT02276547 is a clinical study titled "Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System". The purpose of this study is to evaluate the safety and initial performance of the Neovasc Tiara Mitral Transcatheter Heart Valve with the Tiara Transapical Delivery System.

What is the current status of trial NCT02276547?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 27 participants. The study started on 2014-12. Estimated completion is 2025-08.

What conditions does trial NCT02276547 study?

This clinical trial studies the following conditions: Mitral Valve Regurgitation.

What interventions are being tested in trial NCT02276547?

The interventions under investigation include: Mitral valve replacement (DEVICE).

Who is sponsoring clinical trial NCT02276547?

This trial is sponsored by Shockwave Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02276547 being conducted?

This trial has 10 study locations across California, Illinois, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mitral Valve Regurgitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.